Esperion Therapeutics, Inc.
NASDAQEsperion Therapeutics heads into its May 5 Q1 report not as an independent company in transformation, but as an acquisition target trading at the edge of its deal price. The entire story shifted on May 1. Private equity firm ARCHIMED announced it would acquire Esperion for $3.16 per share in cash, with the right to up to $100 million in additional milestone payments. The stock…
Snapshot as of 8 May 2026
Esperion Therapeutics heads into its May 5 Q1 report not as an independent company in transformation, but as an acquisition target trading at the edge of its deal price. The entire story shifted on May 1. Private…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ESPR — free to start on ORTEX.
Sign up for free →Open ESPR on ORTEX